November 25, 2016 - By Hazel Jackson · 0 Comments
Alexion Pharmaceuticals Inc (NASDAQ:ALXN) institutional sentiment decreased to 1.07 in 2016 Q2. Its down -0.12, from 1.19 in 2016Q1. The ratio has dropped, as 246 institutional investors increased or opened new equity positions, while 206 decreased and sold positions in Alexion Pharmaceuticals Inc. The institutional investors in our partner’s database now hold: 212.84 million shares, down from 223.26 million shares in 2016Q1. Also, the number of institutional investors holding Alexion Pharmaceuticals Inc in their top 10 equity positions decreased from 13 to 12 for a decrease of 1. Sold All: 51 Reduced: 155 Increased: 188 New Position: 58.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $27.08 billion. The Firm is focused on the development and commercialization of life-transforming therapeutic products. It has a 73.03 P/E ratio. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment.
The stock decreased 0.08% or $0.09 during the last trading session, hitting $118.83. About 472,343 shares traded hands. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has declined 25.25% since April 22, 2016 and is downtrending. It has underperformed by 30.66% the S&P500.
Analysts await Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report earnings on February, 1. They expect $1.10 earnings per share, up 30.95% or $0.26 from last year’s $0.84 per share. ALXN’s profit will be $250.68M for 27.01 P/E if the $1.10 EPS becomes a reality. After $1.18 actual earnings per share reported by Alexion Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -6.78% negative EPS growth.
According to Zacks Investment Research, “Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company’s lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.”
Tam Capital Management Inc. holds 100% of its portfolio in Alexion Pharmaceuticals, Inc. for 21,408 shares. Baker Bros. Advisors Lp owns 6.54 million shares or 8.01% of their US portfolio. Moreover, March Altus Capital Management Lp has 7.76% invested in the company for 8,599 shares. The New York-based Lagoda Investment Management L.P. has invested 6.86% in the stock. Bb Biotech Ag, a Switzerland-based fund reported 1.18 million shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 0 buys, and 19 selling transactions for $9.39 million net activity.
Ratings analysis reveals 75% of Alexion Pharmaceuticals Inc.’s analysts are positive. Out of 20 Wall Street analysts rating Alexion Pharmaceuticals Inc., 15 give it “Buy”, 0 “Sell” rating, while 5 recommend “Hold”. The lowest target is $82 while the high is $257. The stock’s average target of $177.47 is 49.35% above today’s ($118.83) share price. ALXN was included in 40 notes of analysts from July 27, 2015. Brean Capital maintained it with “Buy” rating and $221 target price in Friday, July 31 report. UBS maintained the shares of ALXN in a report on Thursday, February 4 with “Buy” rating. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Buy” rating by UBS on Friday, July 31. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has “Market Perform” rating given on Thursday, April 7 by BMO Capital Markets. Goldman Sachs upgraded the stock to “Buy” rating in Friday, October 28 report. The firm earned “Neutral” rating on Friday, October 28 by Wedbush. The stock has “Strong Buy” rating given by Raymond James on Tuesday, September 1. Jefferies maintained the stock with “Hold” rating in Friday, September 23 report. The stock of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) earned “Overweight” rating by Morgan Stanley on Friday, October 2. BTIG Research downgraded the shares of ALXN in a report on Thursday, January 7 to “Neutral” rating.
Alexion Pharmaceuticals, Inc., incorporated on January 28, 1992, is a biopharmaceutical company. The Firm is focused on the development and commercialization of life-transforming therapeutic products. The Firm operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500.
More notable recent Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) news were published by: Businesswire.com which released: “Robbins Arroyo LLP: Alexion Pharmaceuticals, Inc. (ALXN) Misled Shareholders …” on November 22, 2016, also Prnewswire.com with their article: “ALEXION NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered …” published on November 16, 2016, Marketwatch.com published: “Alexion Pharma shares halted, company to delay quarterly results” on November 09, 2016. More interesting news about Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) were released by: Businesswire.com and their article: “Alexion Receives NASDAQ Notification Related to the Late Filing of Form 10-Q” published on November 16, 2016 as well as Prnewswire.com‘s news article titled: “Harwood Feffer LLP Announces Investigation of Alexion Pharmaceuticals, Inc.” with publication date: November 10, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Hazel Jackson